Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Menu
Open search dialog Magnifying Glass My UK HealthCare

COVID-19

× Close UK HealthCare COVID-19 ("Coronavirus") Information Hub Arrow Pointing Right

Robert S. DiPaola, MD

Dean, College of Medicine
Why are there no ratings?
Dr. Robert DiPaola
Request an Appointment Physician Referral

Specialties

  • Genitourinary and Prostate Cancer Team
  • Medical Oncology

  • About

    Faculty Rank

    Professor of Medicine

    Degree

    University of Utah, Salt Lake City

    Residency

    Duke University Medical Center, Durham, N.C.

    Fellowship

    Hematology and Oncology, University of Pennsylvania, School of Medicine, Philadelphia

    Certifications and Special Training

    American Board of Internal Medicine

    American Board of Internal Medicine, Medical Oncology

Are you happy with the care you received from this provider?

Please let us know by filling out a patient satisfaction survey when you get one. You can also leave an online review by clicking the button below.

Leave a review

  • Publications

    1. Atg7 cooperates with Pten loss to drive prostate cancer growth. Santanam U, Banach-Petrosky W, Abate-Shen C, Shen MM, White E, and DiPaola RS. Genes & Development. 2016 Feb 15;30(4):399-407. PubMed PMID: 26883359; PubMed Central PMCID: PMC4762425.
    2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. N Engl J Med. 2015 Aug 20; 373(8):737-46. Epub 2015 Aug 5. PMID: 26244877.
    3. Survival following primary androgen deprivation therapy among men with localized prostate cancer. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS and Yao SL. JAMA. 2008 Jul 9;300(2):173-81. PubMed PMID: 18612114; PubMed Central PMCID: PMC2645653.
    4. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. Kumar P, Perrotti M, Weiss R, Todd M, Goodin S Cummings K and DiPaola RS. J Clin Oncol. 2004 May 15;22(10):1909-15. PubMed PMID: 15143084.
    5. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, et al. N Engl J Med. 1998 Sep 17;339(12):785-91. PubMed PMID: 9738085.

  • Research

    Cancer Center Member

    Research Focus

    Drug Resistance in Cancer Therapy - preclinical studies that support translational clinical trials and investigations into prostate cancer drug resistance.

    Programs

    • Drug Discovery, Delivery and Translational Therapeutics

    College & Department

    • College of Medicine
    • Department of Internal Medicine

    For Referring Physicians

    800 Rose Street
    MN 150
    Lexington, KY 40536-0298
    United States